Beijing Centergate Technologies (000931.SZ): Marketing authorization application for Edaravone Dexborneol Concentrated Solution for Injection accepted
Beijing Centergate Technologies (000931.SZ) announced that its subsidiary Beijing Hualsu Pharmaceutical Co., Ltd. recently received a Notice of Acceptance issued by the National Medical Products Administration, and the marketing authorization application for Edaravone Dexborneol Concentrated Solution for Injection (specification: 5ml: Edaravone 10mg and Dexborneol 2.5mg) has been accepted. The drug is indicated to improve neurological symptoms, activities of daily living, and functional disability caused by acute ischemic stroke.
Beijing Centergate Technologies (000931.SZ) announced that its subsidiary, Beijing Hualsu Pharmaceutical Co., Ltd., recently received a Notice of Acceptance issued by the National Medical Products Administration. The marketing authorization application for Edaravone Dexborneol Concentrated Solution for Injection (specification: 5ml: Edaravone 10mg and Dexborneol 2.5mg) has been accepted. The drug is indicated for improving neurological symptoms, activities of daily living, and functional impairment caused by acute ischemic stroke.
Related Articles
US Stock Market Move | Nasdaq Composite Index extends gains to 1.2%; semiconductor concept stocks rise
AI compute expansion opens up growth space! Bernstein raises SpaceX (SPCX.US) price target to $268; Morgan Stanley maintains "Overweight" rating.
US Stock Market Move | Morgan Stanley names NVIDIA Corporation (NVDA.US) as top semiconductor pick amid the "power shortage bottleneck," shares rise nearly 3%
US Stock Market Move | Nasdaq Composite Index extends gains to 1.2%; semiconductor concept stocks rise
AI compute expansion opens up growth space! Bernstein raises SpaceX (SPCX.US) price target to $268; Morgan Stanley maintains "Overweight" rating.
US Stock Market Move | Morgan Stanley names NVIDIA Corporation (NVDA.US) as top semiconductor pick amid the "power shortage bottleneck," shares rise nearly 3%
